BioMarin Pharmaceutical Company Profile (NASDAQ:BMRN)

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its quarterly earnings data on Thursday, May, 4th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.33. The company earned $303.70 million during the quarter, compared to analysts' expectations of $292.58 million. BioMarin Pharmaceutical had a negative net margin of 46.22% and a negative return on equity of 8.54%. The business's revenue was up 28.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.53) EPS. View BioMarin Pharmaceutical's Earnings History.

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for BioMarin Pharmaceutical.

20 equities research analysts have issued 12 month price objectives for BioMarin Pharmaceutical's shares. Their forecasts range from $84.00 to $150.00. On average, they expect BioMarin Pharmaceutical's share price to reach $112.89 in the next twelve months. View Analyst Ratings for BioMarin Pharmaceutical.

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:

• 1. Wedbush analysts commented, "The Wedbush View: While we see meaningful clinical, regulatory and commercial progress this year, we remain NEUTRAL on BMRN as we believe the stock is relatively expensive as it consistently trades at the top of peers." (5/8/2017)
• 2. Cowen and Company analysts commented, "BMRN reported Q1 Total Revenue ($304MM vs. $289MME) and Non-GAAP EPS." (5/5/2017)
• 3. Jefferies Group LLC analysts commented, "Narrower 1Q GAAP net loss reflects higher revenue & lower OpEx (non- GAAP income of $35M). Next clinical update includes BMN 270 data at ISTH on 7/8-7/13/17." (5/5/2017)
• 4. According to Zacks Investment Research, "BioMarin’s orphan disease drugs – Vimizim and Kuvan – are doing well, backed by strong underlying patient demand trends. BioMarin should continue to see growth in both the drugs in 2017, driven by robust patient growth and penetration. Pipeline development is also on track. Brineura has been approved by the FDA and is under review in EU. Meanwhile, the stock outperformed the broader industry in the past one year. However, Naglazyme revenues vary on a quarterly basis primarily due infrequent ordering patterns from some countries in Latin America and Middle East. Investor focus will be on the stock as several data readouts are lined up for the coming quarters. Loss estimates have remained stable lately ahead of the company’s first quarter result. However, BioMarin has a positive record of earnings surprises in the recent quarters." (5/1/2017)
• 5. JPMorgan Chase & Co. analysts commented, "By Lotus Inventory Impacting Margins In Q1, all rev lines came in above expectations. While Med-Surg has been a consistent outperformer of late, CRM upside was another bright spot. The strong growth came against a tough comp. Headline margins were disappointing due to a spate of issues including the Lotus recall (not surprising), Fuse scope losses (somewhat more surprising) and litigation charges (also not surprising). The Lotus and Fuse charges are not expected to recur; excluding these, we view margins as fairly in-line. While the revenue raise positions BSX shares more favorably in our view, we continue to see the potential for risk around Lotus. While we expect strong data at EuroPCR, we wonder if mgmt’s FDA timelines are aggressive as we would think the FDA might ask for meaningful additional clinical work on the new delivery system following the EU recall. We remain positive on BSX’s underlying fundamentals but feel its current P/E valuation is appropriate until Lotus issues are entirely resolved or Symetis closes and sales ramp." (5/1/2017)

Some companies that are related to BioMarin Pharmaceutical include Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Illumina (ILMN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), BIO-TECHNE Corp (TECH), Kite Pharma (KITE), Galapagos NV (GLPG), Opko Health (OPK), Nektar Therapeutics (NKTR), bluebird bio (BLUE), ACADIA Pharmaceuticals (ACAD) and China Biologic Products (CBPO).

BioMarin Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.93%), Jennison Associates LLC (5.71%), Primecap Management Co. CA (5.04%), State Street Corp (2.29%), Palo Alto Investors LLC (1.37%) and Manning & Napier Advisors LLC (0.98%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.

BioMarin Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co. NY, Marshall Wace LLP, Manning & Napier Advisors LLC, TCW Group Inc., Point72 Asset Management L.P., First Trust Advisors LP, Scout Investments Inc. and APG Asset Management N.V.. Company insiders that have sold BioMarin Pharmaceutical stock in the last year include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical.

BioMarin Pharmaceutical's stock was acquired by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Jennison Associates LLC, Vanguard Group Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Palo Alto Investors LLC, State Street Corp and York Capital Management Global Advisors LLC. View Insider Buying and Selling for BioMarin Pharmaceutical.

Shares of BioMarin Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BioMarin Pharmaceutical stock can currently be purchased for approximately $88.00.